Allergy Therapeutics
Allergy Therapeutics sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 3 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Type I Hypersensitivity, with 2 trials.
Trial Pipeline
12 total, page 1 of 1
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
NCT05476497
Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen
NCT05540717
An Exploratory Study of PQ Grass 27600 SU
NCT04687059
A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL
NCT03931993
Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™
NCT02582073
A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL
NCT02557633
Efficacy and Safety/Tolerability of Ragweed MATA MPL
NCT00423787
Efficacy and Safety/Tolerability of Grass MATA MPL
NCT00414141
Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test
NCT00258635
Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen
NCT00113750
Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing
NCT00104390
Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen
NCT00104377
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 5 |
| Phase 3 | 3 |
Therapeutic Areas
What the Pipeline for Allergy Therapeutics Shows
According to the ClinicalTrials.gov registry, Allergy Therapeutics is linked to 12 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting, about 0% of the sponsor's indexed portfolio, and 11 are already marked complete, representing roughly 92% of the total.
The phase mix for Allergy Therapeutics reports 3 late-stage studies (Phase 3 and Phase 4 combined) and 9 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for Allergy Therapeutics is Type I Hypersensitivity with 2 linked trials, and 2 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.